Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : COVID-19 Vaccine Wins FDA Advisory Panel's Backing as Booster for Adults

10/15/2021 | 02:29pm EST


ę MT Newswires 2021
All news about JOHNSON & JOHNSON
04:45aCOVID-19 Vaccine Makers Working on Strategies Amid Omicron Variant
MT
03:06aEthiopia Launches a Covid-19 Vaccination Campaign Targeting the 12 Years and Above Popu..
AQ
11/26FDA Places Clinical Hold on Phase 3 Study for Ocugen COVID-19 Vaccine Covaxin
MT
11/25Johnson & Johnson COVID-19 Vaccine Fully Approved by Health Canada to Prevent COVID-19 ..
AQ
11/25CORONAVIRUS : Tanzania Broadens Choice for COVID - 19 Vaccines The government has so far a..
AQ
11/24Canada Health Allows Import of Johnson & Johnson's COVID-19 Vaccines Made by US Contrac..
MT
11/24Janssen COVID-19 vaccine plant in Baltimore gets Health Canada OK
AQ
11/24Johnson & Johnson, Pfizer Asked by South Africa to Delay COVID-19 Vaccine Deliveries Du..
MT
11/23JOHNSON & JOHNSON : European Commission Approves BYANNLI« (6-monthly Paliperidone Palmitat..
PU
11/23Almost 100 Million Doses of Johnson & Johnson COVID-19 Vaccine to be Donated to Lower I..
AQ
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 251 M - -
Net income 2021 22 542 M - -
Net Debt 2021 493 M - -
P/E ratio 2021 19,2x
Yield 2021 2,62%
Capitalization 419 B 419 B -
EV / Sales 2021 4,45x
EV / Sales 2022 4,14x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 159,20 $
Average target price 184,65 $
Spread / Average Target 16,0%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON1.16%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049
ABBVIE INC.8.74%205 976